Test Price
2,800 AED✅ Home Collection Available
CRYAA Gene (Autosomal Recessive Congenital Cataract Type 1) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل الحمض النووي NGS لجين CRYAA – الساد الخلقي المتنحي من النوع الأول في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection; VIP Mobile Phlebotomy available 8 AM–11 PM.
- Clinical Guidance: Complimentary telephonic post-test guidance with a DHA-licensed specialist for result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
الملخص التنفيذي (بالعربية): تحليل جيني متقدم بتقنية التسلسل من الجيل التالي (NGS) لجين CRYAA للكشف عن الطفرات المسببة لإعتام عدسة العين الخلقي المتنحي من النوع الأول. يضمن الفحص حساسية تشخيصية بنسبة 99.9% من خلال معالجة معتمدة بمعيار ISO 9001:2015. تشمل الخدمة سحب عينات منزلية عالية الجودة وفق معايير سلسلة التبريد المعتمدة، واستشارة هاتفية مجانية بعد النتيجة، والتحقق المباشر من التغطية التأمينية عبر الواتساب.
Test Overview
The CRYAA Genetic Test sequences the entire coding region of the CRYAA gene to identify pathogenic variants causing autosomal recessive congenital cataract type 1 (CTRCT1). This test is essential for early diagnosis in newborns and infants presenting with bilateral dense cataracts, guiding timely surgical intervention and genetic counselling. يُعد هذا الفحص ضرورياً للتشخيص المبكر لدى حديثي الولادة والرضع الذين يعانون من ساد خلقي كثيف ثنائي الجانب، مما يُوجه التدخل الجراحي في الوقت المناسب والاستشارة الوراثية.
| Feature | Our Test (AMCA Labs UAE) | Closest Alternative (Standard Single-Gene Sequencing) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; full coding region + flanking intronic sites covered | 95–98% sensitivity; may miss deep intronic mutations |
| Method | Next-Generation Sequencing (NGS) with Sanger confirmation of pathogenic variants | Sanger sequencing only (lower throughput, longer TAT for full gene) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Sample Type | Whole Blood, Extracted DNA, or one drop of blood on FTA Card | Whole Blood only |
Physician Insight & Safety Protocol
"As a DHA-licensed specialist, I emphasize that this genetic test is a powerful diagnostic tool, but it must be interpreted in the full clinical context. A positive result confirms the molecular diagnosis, enabling planning for cataract extraction and long-term ophthalmic care, while a negative result does not exclude the condition if other genetic or environmental causes exist. Never make therapeutic decisions solely based on this report; always correlate with clinical findings."
— Dr. Prabhakar Reddy, DHA License 61713011
⚠️ Critical Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This test does not provide information on drug efficacy or therapeutic management. Any changes to your child’s treatment plan must be supervised by the treating ophthalmologist.
Safety Exclusion Criteria
- Patient must not have undergone blood transfusion within the last 3 weeks (may affect genetic material purity).
- Do not collect sample if the child has an active severe infection or sepsis.
- Not appropriate for prenatal samples unless specifically ordered as part of a comprehensive prenatal genetic panel.
Emergency Red Flags (Seek Immediate Medical Attention)
- If your child develops sudden eye redness, pain, or vision loss after the test, visit the emergency room immediately.
- Any adverse reaction to blood draw (fainting, severe bleeding) requires urgent care.
Patient FAQ & Clinical Guidance
What is the purpose of the CRYAA gene test?
The CRYAA NGS test identifies mutations in the CRYAA gene responsible for autosomal recessive congenital cataract type 1, confirming the diagnosis in infants with bilateral cataracts at birth. يحدد اختبار CRYAA NGS الطفرات في جين CRYAA المسؤولة عن الساد الخلقي المتنحي من النوع الأول، مما يؤكد التشخيص لدى الرضع المصابين بساد ثنائي الجانب عند الولادة.
How is the sample collected and is it painful?
A certified phlebotomist collects a small amount of blood (or a drop on an FTA card) via a near-painless finger prick or venipuncture; the procedure takes less than 5 minutes and is safe even for newborns. يقوم فني مختبر معتمد بسحب كمية صغيرة من الدم (أو قطرة على بطاقة FTA) عن طريق وخز إصبع غير مؤلم تقريباً أو سحب وريدي؛ يستغرق الإجراء أقل من 5 دقائق وهو آمن حتى لحديثي الولادة.
How soon will I get the results and what do they mean?
Results are available within 3–4 weeks; a positive report indicates detection of a disease-causing variant, while a negative result may require further evaluation by a geneticist or ophthalmologist for alternative diagnoses. تتوفر النتائج في غضون 3-4 أسابيع؛ التقرير الإيجابي يشير إلى الكشف عن طفرة مسببة للمرض، بينما قد تتطلب النتيجة السلبية تقييماً إضافياً من قبل أخصائي الوراثة أو طب العيون لتشخيصات بديلة.
Pre‑Test Information
A mandatory genetic counselling session is required prior to testing to draw a detailed three‑generation pedigree chart and document the clinical history of the patient and affected family members with CRYAA‑related congenital cataract. No special dietary or medication restrictions; however, inform the phlebotomist of any anticoagulant therapy. The can be performed on whole blood, extracted DNA, or a single drop of blood applied to an FTA card; ensure the card is completely dry before shipment.
© 2026 AMCA Labs. All rights reserved. Licensed by DHA (9834453). ISO 9001:2015 Certified. Federal Law No. 41/2024, UAE PDPL, CDS Law 2026 (Minors) compliance.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians